EU Steps Up Electronic Product Information Plans; Promises Flexibility
Executive Summary
Comments are being invited on draft key principles that will form the basis on which ePI for medicines will be developed and used in the EU.
You may also be interested in...
Pharma Wary Of Over-Flexible EU Plan For Electronic Product Information
The pharmaceutical industry is concerned that too much flexibility may result in a “fragmented and cost intensive implementation” of the EU electronic product information framework.
Singaporean Regulator Invites Companies To Join Electronic Labeling Trial
The Health Sciences Authority is evaluating the reliability and feasibility of disseminating package inserts and patient information leaflets electronically.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.